Biocon Biologics and Viatris announce the launch of Abevmy® (biosimilar bevacizumab) in Canada. Abevmy® was jointly developed by Biocon Biologics and Viatris, and is indicated for metastatic colorectal cancer, locally advanced, metastatic or recurrent non-small cell lung cancer, platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer and malignant glioma-glioblastoma. This is the fourth Canadian biosimilar launched by Viatris.
Under the portfolio development agreement (which includes a “broad portfolio of biosimilars and insulin analogs”), Viatris has exclusive commercialisation rights in the U.S., Canada, Australia, New Zealand, EU and the European Free Trade Association countries, whilst Biocon Biologics has them in certain emerging markets. They share co-exclusive commercialisation rights in the rest of the world.